Join our community of smart investors

AstraZeneca: healthy half-years

Growth registered across all three therapy areas
AstraZeneca: healthy half-years

In recent weeks, mention of AstraZeneca (AZN) has invariably been linked with the words ‘Oxford University’ or ‘Covid-19’. Little wonder - the UK pharma giant is working hard to tackle the new coronavirus, most prominently via a vaccine partnership led by the Jenner Institute in the City of Dreaming Spires. Early-stage human studies have produced encouraging results, and the next phase of trials is already under way. AstraZeneca has committed to supply more than 2bn doses of the vaccine, should it prove successful. 

IC TIP: Buy at 8850p

To continue reading...
OR
Register for free
Read 3 articles for free each month
* Excl. premium articles
Have an account? Sign in